CYP Update Reporting from USAID Missions on CYP

CYP Update

Reporting from USAID Missions on CYP Conversion Factors Bangladesh Ethiopia Ghana Guatemala Kenya India Uganda Madagascar Nepal Nigeria Oral Contraceptives √ √ 13 √ √ √ √ Condoms √ √ √ √ 240 √ √ Female Condoms √ √ √ √ Vaginal Foaming Tabs √ √ √ √ Noristerat Injectable √ √ √ √ Cyclofem 1 -Mnth Inject. √ √ √ √ √ Depo Provera Inject. √ √ √ Copper-T 380 -A IUD √ √ Norplant Implant √ √ √ √ 2. 8 √ √ 3. 5 √ √ √ 2. 8 √ √ √ √ 1. 73 √ √ √ Implanon Implant Jadelle Implant √ FAM (eg SDM) √ √ LAM √ √ Sterilization R √ √ R R ECPs √ √ √ √ = uses USAID conversion factors R = uses USAID regional default values Blank = does not report on that method √ √ R R 20 P-only 8 combined pill . 375 PSI √

Principles for CYP Conversion Factor Development, USAID 2011 • • • Seen only as an update Keep simple for calculations Strive for uniformity across countries etc. Base on most realistic programmatic data Meaningfully related to unintended pregnancies averted, (but not actual measurement of unintended pregnancies averted. ) • Recognize these are only approximations – avoid false precision • Recognize “intangibles” exist (e. g. dual method use, extended effectiveness of injectables) • Kind of a “coverage” indicator – level playing field of credit

Other objectives not addressed by CYP • Quality - including choice • Continuation • Actual impact on unintended pregnancy

Thank you